Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
Alimentary Pharmacology & Therapeutics · 2024-07 · 60 (1) · 33-42
DOI: 10.1111/apt.18011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 22.04.2024. Verfasst von Donghee Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Nutrition Surveys, Fatty Liver. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
Background
Recently, a panel of multi‐society experts proposed steatotic liver disease (SLD) as an alternative terminology for metabolic dysfunction‐associated fatty liver disease (MAFLD) or nonalcoholic fatty liver disease (NAFLD).
Aims
We compared the impact of SLD, subtype of SLD, MAFLD and NAFLD on all‐cause and cause‐specific mortality.
Methods
A total of 7811 individuals in the third National Health and Nutrition Examination Survey and linked mortality through 2019 were analysed. SLD was defined based on ultrasonographic hepatic steatosis. SLD, subtype of SLD and MAFLD were defined using the proposed definitions. The Cox proportional hazard model assessed all‐cause/cause‐specific mortality.
Results
During a median follow‐up of 27.1 years, individuals with SLD and MAFLD experienced approximately 13%–23% higher risk of all‐cause mortality (hazard ratio [HR]: 1.15, 95% confidence interval [CI]: 1.02–1.29 for SLD; HR: 1.23, 95% CI: 1.09–1.38 for MAFLD; HR: 1.13, 95% CI: 1.01–1.27 for metabolic dysfunction‐associated steatotic liver disease [MASLD]). Individuals with MetALD demonstrated a higher risk of all‐cause (HR: 1.68, 95% CI: 1.10–2.57) and cancer‐related mortality (HR: 2.40, 95% CI: 1.23–4.66). MASLD with advanced fibrosis had an increased risk of all‐cause mortality compared to MASLD without advanced fibrosis.
Conclusions
SLD, especially MASLD and MetALD, is associated with increased all‐cause mortality among adults in the US. Given this significant association between SLD or subtype of SLD (MASLD and MetALD) and all‐cause mortality, adopting the proposed SLD criteria may help identify a sub‐group of individuals with SLD who are at an increased risk for all‐cause mortality.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California, USA.
- Department of Medicine, Division of Gastroenterology and Hepatology, University of Arizona College of Medicine, Phoenix, Arizona, USA.
- Department of Internal Medicine, Division of Gastroenterology and Hepatology, Banner University Medical Center, Phoenix, Arizona, USA.
- Liver Center, Division of Abdominal Transplantation, Michael E DeBakey Department of General Surgery, Baylor College of Medicine, Houston, Texas, USA.
- Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas, USA.
ORCID-Profile: Donghee Kim, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed
Zitieren
APA
Kim, D., Wijarnpreecha, K., Cholankeril, G., & Ahmed, A. (2024). Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States. Alimentary Pharmacology & Therapeutics, 60(1), 33-42. https://doi.org/10.1111/apt.18011
Vancouver
Kim D, Wijarnpreecha K, Cholankeril G, Ahmed A. Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States. Alimentary Pharmacology & Therapeutics. 2024;60(1):33-42. doi:10.1111/apt.18011
BibTeX
@article{Kim2024,
author = {Kim, Donghee and Wijarnpreecha, Karn and Cholankeril, George and Ahmed, Aijaz},
title = {Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2024},
volume = {60},
number = {1},
pages = {33--42},
doi = {10.1111/apt.18011}
}
EUVIMED